US 11,732,033 B2
Immunogenic peptide against group a Streptococcus
Michael F. Good, The Gap (AU); Manisha Pandey, Calamvale (AU); and Michael Raymond Batzloff, Holmview (AU)
Assigned to GRIFFITH UNIVERSITY, Nathan (AU)
Appl. No. 16/640,819
Filed by GRIFFITH UNIVERSITY, Nathan (AU)
PCT Filed Aug. 22, 2018, PCT No. PCT/AU2018/050893
§ 371(c)(1), (2) Date Feb. 21, 2020,
PCT Pub. No. WO2019/036761, PCT Pub. Date Feb. 28, 2019.
Claims priority of application No. 2019439 (NL), filed on Aug. 23, 2017.
Prior Publication US 2021/0024619 A1, Jan. 28, 2021
Int. Cl. A61K 39/09 (2006.01); A61K 38/16 (2006.01); A61K 39/116 (2006.01); A61K 9/00 (2006.01); A61K 47/64 (2017.01); C07K 14/315 (2006.01); C07K 16/12 (2006.01); A61K 39/385 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1271 (2013.01) [A61K 9/0019 (2013.01); A61K 38/16 (2013.01); A61K 39/092 (2013.01); A61K 39/116 (2013.01); A61K 47/646 (2017.08); C07K 14/315 (2013.01)] 17 Claims
 
1. A method of eliciting a mucosal immune response to group A streptococcal bacteria in a mammal, said method including the step of intramuscularly administering to the mammal an isolated protein comprising:
(a) the amino acid sequence of SEQ ID NO: 1;
(b) the amino acid sequence of SEQ ID NO: 21;
(c) the amino acid sequence of SEQ ID NO: 1 conjugated to a carrier protein; or
(d) the amino acid sequence of SEQ ID NO: 21 conjugated to a carrier protein.